Le Lézard
Classified in: Ebola virus, Health
Subject: PER

Bayer Hires Dan Childs of ABC News as Director of U.S. External Communications



WHIPPANY, N.J., Feb. 1, 2018 /PRNewswire/ -- Bayer announced today that Dan Childs, award-winning medical journalist and Managing Editor of the ABC News Medical Unit, is joining the company as Director of External Communications responsible primarily for U.S. Media Relations.

Dan Childs, Director of U.S. External Communications for Bayer

Childs, who will officially join Bayer on Feb. 5, brings extensive experience in visual storytelling, digital journalism and broadcast news to Bayer. Childs will serve as one of the top media relations professionals for Bayer in the U.S. and report directly to Christopher Loder, Vice President and Head of External Communications for Bayer U.S.

"We are fortunate to have someone of Dan's knowledge and experience in journalism and broadcast media join our Bayer team," Loder said. "Through his stellar work with 'Good Morning America,' 'World News with David Muir' and ABCNews.com, Dan has informed Americans about the most pressing health, science and medical news. He has a storyteller's gift of taking complex information and translating it to a lay audience. Dan will bring innovation and creativity to Bayer."

Childs covered numerous public health issues during his time as a producer and editor at ABC News, most notably the 2014 Ebola outbreak, the 2015 Zika epidemic, the Affordable Care Act and the opioid crisis in America. Last year, Childs received an Emmy for his contributions to the network's hospital and medical reporting in the wake of the Pulse Nightclub Massacre. In 2013, Childs shared in two George Foster Peabody Awards: one for his contributions to the reporting of New York City hospital evacuations during Superstorm Sandy; and the other for "Robin's Journey," a segment about "Good Morning America" Anchor Robin Roberts' fight against myelodysplastic syndromes (MDS), for which he coordinated ABC News' social media efforts promoting the National Marrow Donor Program's Be The Match Registry.

Childs also coordinated and supervised the ABC News Medical Journalism resident rotation ? a unique four-week program that attracted hundreds of physicians from across the United States and trained them to work within a national network news division. Many of these participants went on to become local TV doctors and media contributors in their communities.

In addition to his duties at ABC News, Childs is also an adjunct lecturer at the Tufts University School of Medicine, where he teaches a course on health media messaging at the school's Summer Institute. Childs has also served as a panelist discussing patient and health care consumer empowerment at the Association of Health Care Journalists (AHCJ) annual conference.

Previous to ABC News, Childs worked as an editor and co-host at Cosmetic Surgery and Beauty magazine and as a staff writer at The Daily Courier. He holds a Master of Arts degree in medical journalism from the University of North Carolina-Chapel Hill and a Bachelor of Science degree in biology from Wake Forest University.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.

Contact:

Carolyn Nagle
Bayer U.S.
Email: carolyn.bender@bayer.com
Office: 862-404-5955
Mobile: 201-419-0337

Social Media Channels
- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

 

SOURCE Bayer


These press releases may also interest you

at 13:30
One Drop, a leader in the development of digital therapeutics solutions for people with diabetes, today announced the launch of Blood Glucose Prediction and Automated Decision Support. Through these new features, the One Drop | Mobile app will...

at 13:01
New research finds that people with type 1 diabetes (T1D) who used the Diabeloop DBLG1 therapeutic, closed-loop insulin delivery system in a home setting experienced a greater percentage of time in the target blood glucose range and fewer...

at 12:43
When adolescents and adults with type 1 diabetes (T1D) used a new continuous glucose monitoring (CGM) device containing a sensor that can remain implanted in the arm for up to 180 days, the system provided accurate glucose measurement with no major...

at 12:43
A dual-hormone, artificial pancreas1 delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an insulin-only, first-generation artificial pancreas,...

at 12:40
Adults with type 1 diabetes using the Omnipod hybrid closed-loop system (the Horizontm Automated Glucose Control System) were studied in a supervised outpatient hotel setting with unrestricted meals and moderate-intensity exercise and  experienced...

at 10:12
Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)...




News published on 1 february 2018 at 10:01 and distributed by: